title: Deal watch: Epizyme-Celgene deal signals interest in new class of epigenetic drugs.
authors: Alexandra
authors: A
authors: Flemming
mesh_terms: D000818:Animals; D055808:Drug Discovery / Q000145:classification / Q000191:economics* / Q000639:trends; D004345:Drug Industry / Q000191:economics* / Q000639:trends; D004791:Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use; D057890:Epigenomics / Q000145:classification / Q000191:economics* / Q000639:trends; D015316:Genetic Therapy / Q000191:economics / Q000639:trends; D000076983:Histone Methyltransferases; D011495:Histone-Lysine N-Methyltransferase / Q000037:antagonists & inhibitors; D006801:Humans
chemical_list: D004791:Enzyme Inhibitors; D000076983:Histone Methyltransferases; D011495:Histone-Lysine N-Methyltransferase